Table 4 Risk score model of GSE14520 and TCGA cohort.

From: Identification and validation of candidate clinical signatures of apolipoprotein L isoforms in hepatocellular carcinoma

Dataset

Type

Variables

Coefficient

P values

HR

95% CI

GSE14520

OS

Tumor size

0.140

0.140

1.150

0.691–1.914

Cirrhosis

 − 1.367

 − 1.367

0.255

0.062–1.048

BCLC stage 0

 

 < 0.001

  

Stage A

1.396

1.396

4.038

0.974–16.746

Stage B

1.808

1.808

6.101

1.315–28.305

Stage C

2.625

2.625

13.798

3.009–63.265

AFP

0.209

0.209

1.232

0.788–1.926

APOL3

 − 0.294

 − 0.294

0.745

0.458–1.212

APOL6

 − 0.524

 − 0.524

0.592

0.358–0.980

RFS

Gender

 − 0.603

0.072

0.547

0.284–1.054

Cirrhosis

 − 0.881

0.057

0.414

0.168–1.025

BCLC stage 0

 

0.001

  

Stage A

0.658

0.123

1.931

0.837–4.456

Stage B

1.101

0.025

3.008

1.150–7.871

Stage C

1.561

0.001

4.762

1.892–11.983

APOL2

 − 0.250

0.221

0.779

0.521–1.163

APOL3

 − 0.212

0.321

0.809

0.533–1.230

APOL6

 − 0.400

0.061

0.670

0.441–1.018

TCGA

RFS

Stage I

 

 < 0.001

  

Stage II

0.986

0.002

2.682

1.440–4.993

Stage III + IV

1.299

 < 0.001

3.665

2.015–6.664

Radical resection

1.044

0.004

2.842

1.405–5.748

Microvascular invasion

 − 0.449

0.105

0.639

0.371–1.099

HBV infection

 − 0.049

0.842

0.952

0.588–1.541

APOL3

 − 0.386

0.09

0.680

0.435–1.062

APOL4

 − 0.308

0.184

0.735

0.466–1.158

  1. APOL2: apolipoprotein L 2; APOL3: apolipoprotein L 3; APOL4: apolipoprotein L 4; APOL6: apolipoprotein L 6; HR: hazard ratio; 95%CI: 95% confidence interval; OS: overall survival; RFS: recurrence-free survival; AFP: α-fetoprotein; BCLC: Barcelona Clinic Liver Cancer; HBV: hepatitis B virus.
Back to article page